TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab.

[1]  C. Doglioni,et al.  Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Maisch,et al.  Cytokines in Pericardial Effusion of Patients with Inflammatory Pericardial Disease , 2012, Mediators of inflammation.

[3]  L. Arnaud,et al.  Erdheim–Chester disease , 2012, Current opinion in rheumatology.

[4]  L. Arnaud,et al.  Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. , 2011, Blood.

[5]  M. Ferrarini,et al.  Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. , 2010, Rheumatology.

[6]  M. Feldmann,et al.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[7]  M. Ferrarini,et al.  Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. , 2006, Arthritis and rheumatism.

[8]  P. Grenier,et al.  Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. , 2006, Arthritis and rheumatism.

[9]  P. Grenier,et al.  Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester Disease: Report of 6 New Cases and a Literature Review , 2004, Medicine.

[10]  A. Villa,et al.  Chromogranin A protects vessels against tumor necrosis factor α‐induced vascular leakage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.